References
- Christensen D, Agger EM, Andreasen LV, et al. (2009). Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 19:2–11
- Coffman RL, Lebman DA, Rothman P. (1993). Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54:229–70
- Constant SL, Bottomly K. (1997). Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15:297–322
- Davis HL, McCluskie MJ, Gerin JL, Purcell RH. (1996). DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 93:7213–18
- Donnelly J, Berry K, Ulmer JB. (2003). Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 33:457–67
- Ferraro B, Morrow MP, Hutnick NA, et al. (2011). Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53:296–302
- Gill HS, Prausnitz MR. (2007). Coated microneedles for transdermal delivery. J Control Release 117:227–37
- Guo L, Chen JM, Qiu YQ, et al. (2013b). Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant. Int J Pharmaceut 447:22–30
- Guo L, Qiu YQ, Chen JM, et al. (2013a). Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays. Biomed Microdevices 15:1077–85
- Gursel I, Gursel M, Ishii KJ, Klinman DM. (2001). Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167:3324–8
- Hoofnagle JH, DiBisceglie AM. (1997). The treatment of chronic viral hepatitis. New Engl J Med 336:347–56
- Klinman DM, Yi AK, Beaucage SL, et al. (1996). CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93:2879–83
- Kupper TS, Fuhlbrigge RC. (2004). Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4:211–22
- Li N, Zhuang CY, Wang M, et al. (2012). Low molecular weight chitosan-coated liposomes for ocular drug delivery: In vitro and in vivo studies. Drug Deliv 19:28–35
- Michel ML, Loirat D. (2001). DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology 44:78–87
- Moon S, Wang YH, Edens C, et al. (2013). Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine 31:3396–402
- Pavselj N, Preat V. (2005). DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. J Control Release 106:407–15
- Pearton M, Kang SM, Song JM, et al. (2010). Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine 28:6104–13
- Sullivan SP, Koutsonanos DG, Martin MD, et al. (2010). Dissolving polymer microneedle patches for influenza vaccination. Nat Med 16:915–20
- Van den Berg JH, Nuijen B, Beijnen JH, et al. (2009). Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 20:181–9
- Van der Maaden K, Jiskoot W, Bouwstra J. (2012). Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 161:645–55
- Yan G, Arelly N, Farhan N, et al. (2014). Enhancing DNA delivery into the skin with a motorized microneedle device. Eur J Pharm Sci 52:215–22
- Yin DF, Liang WQ, Xing SX, et al. (2013). Hepatitis B DNA vaccine-polycation nano-complexes enhancing immune response by percutaneous administration with microneedle. Biol Pharm Bull 36:1283–91